Hu Cheng-Jin, Zhang Fang, Chen Ying-Jian, Sun Xiao-Ming, Zheng Jin-Feng
Department of Laboratory Medicine, General Hospital of Jinan Military Region, Jinan 250031, China.
Zhonghua Zhong Liu Za Zhi. 2009 Jul;31(7):520-3.
To approach the relationship between the expression of hK6 in ovarian neoplasm and clinicopathological variables and prognosis in ovarian cancer patients for finding a new tumor marker of the ovarian cancer.
The expression of hK6 was detected by immunohistochemistry in 19 cases of benign, 11 cases of borderline and 45 cases of malignant ovarian neoplasms and statistically analyzed whether its expression correlate with clinicopathological variables and prognosis in patients with ovarian cancer.
The expression of hK6 in ovarian cancer tissues (60.0%) was significantly higher than that in the benign (15.8%) and borderline (27.3%) ovarian neoplasm tissues (P < 0.01). The expression of hK6 in higher-grade ovarian cancer tissues (68.4% ) was higher than that in low-grade ones (14.3%, P < 0.05). The expression of hK6 in late-stage (stage III, 76.7%) was significantly higher than that in early-stage (stage I or II, 26.7%, P < 0.01). The expression of hK6 was significantly higher in patients with lymph node metastasis (77.8%) than that in patients without (33.3%, P < 0.01). The expression of hK6 in the cancer tissues in the patients died, or with reccurence or metastasis within 3 years after surgery was higher (75.0%) than that in the patients with stable disease (42.9%, P < 0.05).
The expression of hK6 in ovarian cancer was higher than that in benign and borderline ovarian neoplasms. The expression of hK6 is higher in the ovarian cancer of late stage, higher-grade, with lymph node metastasis and is associated with a poorer prognosis. hK6 may become a new markers in prediction of prognosis of the patients with ovarian tumors.
探讨人角蛋白6（hK6）在卵巢肿瘤中的表达与临床病理变量及卵巢癌患者预后的关系，以寻找一种新的卵巢癌肿瘤标志物。
采用免疫组织化学法检测19例卵巢良性肿瘤、11例交界性肿瘤及45例恶性肿瘤组织中hK6的表达，并对其表达与卵巢癌患者临床病理变量及预后的相关性进行统计学分析。
hK6在卵巢癌组织中的表达率（60.0%）显著高于良性（15.8%）和交界性（27.3%）卵巢肿瘤组织（P<0.01）。hK6在高级别卵巢癌组织中的表达率（68.4%）高于低级别组织（14.3%，P<0.05）。hK6在晚期（Ⅲ期，76.7%）的表达显著高于早期（Ⅰ或Ⅱ期，26.7%，P<0.01）。有淋巴结转移患者的hK6表达率（77.8%）显著高于无淋巴结转移患者（33.3%，P<0.01）。术后3年内死亡、复发或转移患者癌组织中hK6的表达率（75.0%）高于病情稳定患者（42.9%，P<0.05）。
hK6在卵巢癌中的表达高于良性和交界性卵巢肿瘤。hK6在晚期、高级别、有淋巴结转移的卵巢癌中表达较高，且与预后较差相关。hK6可能成为预测卵巢肿瘤患者预后的新标志物。
